Mechanisms of Staphylococcus aureus resistance to fluoroquinolones were characterized. Subunit A and B proteins of DNA gyrase were partially purified from fluoroquinolone-susceptible strain SA113 and resistant isolate MS16405, which was 250-to 1,000-fold less susceptible to fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, temafloxacin, and sparfloxacin than SA113 was. The supercoiling activity of the gyrase from SA113 was inhibited by the fluoroquinolones, and the 50% inhibitory concentrations of the drugs correlated well with their MICs. In contrast, the gyrase from MS16405 was insensitive to inhibition of supercoiling by all of the quinolones tested, even at 800 ,ug/ml. Combinations of heterologous gyrase subunits showed that subunit A from MS16405 conferred fluoroquinolone resistance, suggesting that an alteration in gyrase subunit A is a cause of the fluoroquinolone resistance in MS16405. Uptake of hydrophilic fluoroquinolones such as ciprofloxacin and norfloxacin by MS16405 was significantly lower than that by SA113. Furthermore, this difference was abolished by the addition of an energy inhibitor, carbonyl cyanide m-chlorophenylhydrazone, suggesting that an alteration in an energy-dependent process, such as an active efflux of hydrophilic quinolones, may lead to decreased drug uptake and hence to increased resistance to fluoroquinolones in MS16405. These findings suggest that the fluoroquinolone resistance in MS16405 is due mainly to an alteration in subunit A of DNA gyrase and may also be associated with an alteration in the drug uptake process.
Infections caused by methicillin-resistant Staphylococcus aureus strains are a serious medical problem because only a few effective therapeutic agents are clinically available. Some fluoroquinolones, such as ofloxacin, ciprofloxacin and others, have been used for treatment of methicillin-resistant S. aureus infections. However, along with their greater use, the emergence of fluoroquinolone-resistant strains of S. aureus has been commonly reported (21, 24) .
Studies with Escherichia coli and other gram-negative bacteria have shown that fluoroquinolones exert their antibacterial activities by inhibiting DNA gyrase, an essential bacterial topoisomerase II (27, 31, 32) . The resistance of E. coli and Pseudomonas aeruginosa to fluoroquinolones has been shown to be associated with modification of DNA gyrase or alteration of outer membrane permeability (3, 7, 8, 10, 11, 13, 16, 22, 23) . In regard to S. aureus, the exact role of DNA gyrase in fluoroquinolone action and resistance has not been fully explained, although its DNA gyrase has been partially purified by several workers (6, 28) . Recently, Tanaka et al. (29) reported a close correlation of antibacterial activities of fluoroquinolones with their inhibitory activities against DNA gyrase of S. aureus FDA 209P and suggested that in S. aureus, as in gram-negative bacteria, DNA gyrase is a target enzyme of fluoroquinolones.
Hopewell et al. (12) succeeded in cloning S. aureus genes which encode the DNA gyrase A and B proteins. Their DNA sequence analysis revealed a close homology between the S. aureus gyrase subunits and their counterparts in Bacillus subtilis and E. coli, including several conserved amino acid residues whose substitutions in E. coli confer resistance to 4-quinolones. They have also suggested that amino acid substitutions in a region of the gyrase A protein are responsible for ciprofloxacin resistance in ciprofloxacin-resistant isolates of S. aureus (25) . Thus, mutations in the DNA gyrase A subunit are implicated in fluoroquinolone resistance in S. aureus. However, enzymatic properties of the gyrase and its role in fluoroquinolone resistance in resistant clinical isolates have not been reported because of the difficulty in obtaining a sufficient quantity of purified gyrase (12, 30) .
The biochemical approach to studying the mechanisms of fluoroquinolone resistance is to analyze the properties of gyrase proteins obtained from quinolone-resistant strains. In the present study, we partially purified DNA gyrase from a methicillin-and fluoroquinolone-resistant S. aureus isolate and analyzed its properties to elucidate the mechanisms of fluoroquinolone resistance. The possible contribution of fluoroquinolone uptake to resistance was also examined. 12 ,000 x g for 15 min, the tubes were drained and the pellets were homogenized in 1 M NaCl in TGED buffer with a glass homogenizer. After being stirred for 30 min, the suspension was centrifuged and the supernatant was collected. Solid ammonium sulfate was added to the supernatant to give 70% saturation (0.47 g/ml) and, after stirring for 1 h, the precipitate was collected by centrifugation at 100,000 x g for 30 min, suspended in 50 ml of TGED buffer, and dialyzed against 3 liters of the same buffer for 12 h.
MATERIALS
The dialysate was applied to a column of novobiocinSepharose 6B (bed volume, 20 ml) previously equilibrated with TGED buffer. Novobiocin-Sepharose was prepared by the procedure of Staudenbauer and Orr (26) . The column was washed with 120 ml of TGED buffer and eluted successively with 0.2 M KCl, 2 M KCl, 5 M urea, 2 M KCl-5 M urea, and 2 M KCl-5 M urea (pH 4.0). Subunit A eluted mainly with 2 M KCI in TGED buffer, and subunit B eluted with 2 M KCl-5 M urea in TGED buffer. In accordance with the nomenclature of the subunits of E. coli gyrase (26) , the active fractions at 2 M KCl and 2 M KCl-5 M urea were designated subunits A and B, respectively, of S. aureus gyrase. Active fractions of subunits A and B were pooled separately, immediately dialyzed against 3 liters of TGED buffer for 12 h, concentrated by dialysis against TGED buffer containing 50% (vol/vol) glycerol, and stored at -20°C. These preparations were stable during storage at -20°C for at least 2 months. The protein assay was performed by the procedure of Bradford (2) .
DNA supercoiling assay and IC50 determination. DNA gyrase supercoiling activity was assayed as described previously (5, 19) . One unit of gyrase was defined as the amount of enzyme that catalyzed the conversion of one-half of 0.1 ,ug of relaxed closed circular pBR322 DNA to the supercoiled form in 1 h at 37°C, as discerned by agarose gel electrophoresis (5). The standard reaction mixture (20 ,ul) contained 20 mM Tris hydrochloride (pH 7.5), 20 mM KCl, 2 mM MgCl2, 2 mM spermidine, 1.5 mM ATP, 1 mM dithiothreitol, 10 ,ug of bovine serum albumin per ml, 30 ,ug of tRNA per ml, 0.1 jig of relaxed pBR322 which had been relaxed by topoisomerase I, a drug solution, and DNA gyrase subunits A and B (1 U of each). A control reaction with no drug was included. After incubation at 37°C for 1 h, the reaction was stopped by addition of 3 ,ul of proteinase K (1 mg/ml) and then the reaction mixture was subjected to agarose gel electrophoresis (0.8% agarose in 40 mM Tris acetate-2 mM EDTA). The gel was stained in 0.5 ,ug of ethidium bromide per ml and photographed upon exposure to UV light. The negative was traced with a densitometer (CS-9000; Shimadzu Seisakusyo Co., Ltd, Kyoto, Japan). Densitometric tracings were used to determine the 50% inhibitory concentrations (IC50s). The IC50 was defined as the concentration of a drug that inhibited 50% of the supercoiling activity of DNA gyrase in a standard reaction mixture (1, 19) .
Uptake of quinolones by S. aureus cells. Fluoroquinolone uptake by intact cells was measured essentially as described previously (7, 19, 34 showed high resistance to all of the quinolones tested; the MICs were 250-to 1,000-fold higher than those for SA113. This strain was also resistant to methicillin, tetracycline, minocycine, and chloramphenicol, while SA113 was susceptible to these antimicrobial agents. However, MS16405 was as susceptible to novobiocin as SA113 was. Purification and properties of DNA gyrase. To determine whether the fluoroquinolone resistance of S. aureus was due to an altered DNA gyrase, partially purified gyrases were prepared from SA113 and MS16405 by affinity chromatography on novobiocin-Sepharose. Figure 1 shows the enzymatic properties of DNA gyrase from SA113. When fractions of subunits A and B were assayed separately (Fig. 1, lanes b and c), no DNA supercoiling activity was observable. Supercoiling activity was observed only when the two subunits were combined (Fig. 1, lane d) . The specific activities of purified subunits A and B were 2.9 x 10o and 8.7 x 10i U/mg of protein, respectively. Interspecies complementation between gyrase subunits of S. aureus and B. subtilis was examined. An active enzyme could be obtained by combining subunit B of S. aureus gyrase with subunit A of B. subtilis gyrase (Fig. 1, lane m) . However, the reciprocal combination of heterologous subunits (i.e., subunit A of S. aureus gyrase plus subunit B of B. subtilis gyrase) did not result in an active holoenzyme (Fig. 1, lane 1) . Furthermore, the combination of subunit B of S. aureus gyrase and subunit A of E. coli gyrase also showed weak supercoiling activity (data not shown). These results indicate that the DNA gyrase of S. aureus consists of the two subunits, analogous to the DNA gyrase from other gram-positive bacteria, such as B. subtilis (20) and Micrococcus luteus (15) , and provide evidence for the functional equivalence of the S. aureus, B. subtilis, and E. coli subunits.
S. aureus DNA gyrase was similar to E. coli, B. subtilis, or M. luteus gyrase in its cofactor requirements. The supercoiling reaction required ATP and Mg2+ (Fig. 1 , lanes e and f at optimum concentrations of 3 and 2 mM, respectively (data not shown). Slightly lower levels of activity were also obtained by addition of Mn2" and Ca2e in place of Mg2+ (Fig. 1, lanes g and h) .
Subunits A and B from MS16405 were also separately purified by the same purification procedure, and their enzymatic properties were similar to those of the subunits from SA113.
Inhibition of DNA supercoDhng activity. The inhibitory effects of ofloxacin on DNA gyrases from SA113 and MS16405 are shown in Fig. 2 . With SA113 gyrase, some inhibition by ofioxacin was seen at 12.5 to 50 p.g/ml (Fig. 2,   lanes d to f) ; nearly complete inhibition was seen at 100 p,g/ml (Fig. 2, lane g ). On the other hand, MS16405 gyrase was hardly inhibited by ofloxacin, even at a concentration of 800 ,ug/ml (Fig. 2, lane p) . The IC50s of several fluoroquinolones, nalidixic acid, and novobiocin against the supercoiling activity of the gyrases from SA113 and MS16406 were determined ( Table 2 ). The IC50s of ciprofloxacin, norfloxacin, ofloxacin, temafloxacin, and sparfloxacin against SA113 gyrase ( Novobiocin, an agent that competitively inhibits ATP binding to subunit B (9), was equally active against all gyrase preparations (IC50, 0.4 to 0.7 ,ug/ml).
Uptake of fluoroquinolones. Fluoroquinolone uptake by SA113 and MS16405 cells was examined in the absence or presence of an energy inhibitor, CCCP (Table 3) . Without CCCP, the levels of uptake by MS16405 were lower than those by SA113 with all of the drugs tested and the lowest amounts of uptake were observed with ciprofloxacin and norfloxacin. However, the level of sparfloxacin uptake by MS16405 was almost the same as that by SA113. In both strains, sparfloxacin uptake was higher than those of the other drugs, regardless of the absence or presence of CCCP, suggesting higher penetrability of S. aureus cells by sparfloxacin than other fluoroquinolones. By addition of CCCP, the levels of fluoroquinolone uptake significantly increased (29) with the DNA gyrase purified from S. aureus FDA 209-P. These findings indicate that the differences in antibacterial activity between individual quinolones reflect variations in the ability to inhibit DNA supercoiling catalyzed by DNA gyrase. Thus, it appears that in S. aureus, as in gramnegative bacteria, the basis of fluoroquinolone activity is inhibition of DNA gyrase.
In this study, we described the mechanisms of fluoroquinolone resistance in a clinical isolate of S. aureus MS16405. The supercoiling activity of the gyrase from MS16405 was insensitive to fluoroquinolones but susceptible to novobiocin, suggesting that the subunit A protein was altered. Heterologous gyrase subunit assays confirmed that the decreased inhibition was conferred by resistant gyrase subunit A. Hence, we conclude that an alteration in subunit A of the gyrase is the major contributor to fluoroquinolone resistance in MS16405. This conclusion is consistent with recent genetic studies by Sreedharan et al. (25) on ciprofloxacinresistant S. aureus isolates. Although they did not characterize the gyrase proteins, they suggested from the DNA sequence analysis of cloned gyrase genes that DNA gyrase subunit A mutations are responsible for the ciprofloxacin resistance of S. aureus.
To determine whether other factors contribute to the fluoroquinolone resistance of S. aureus, we analyzed the fluoroquinolone uptake of these strains. Our results suggest that the decreased uptake of the drugs is not the major contributor to resistance, because the amount of sparfloxacin taken up by MS16405 was virtually no different from VOL. 35, 1991 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from that taken up by SA113. However, we observed that uptake of hydrophilic quinolones, such as ciprofloxacin and norfloxacin, by MS16405 was significantly lower than their uptake by SA113. When deenergized by addition of CCCP, MS16405 accumulated over 15-fold more ciprofloxacin and norfloxacin, while SA113 accumulated only four-to fivefold more of these drugs. Consequently, the difference in uptake level between these strains was abolished. These results suggest the possibility that an alteration in the active efflux system decreased the uptake and hence increased the resistance levels in MS16405. Since the increase rate of sparfloxacin uptake in MS16405 caused by addition of CCCP was almost equal to that in SA113, the uptake of hydrophilic quinolones, but not that of hydrophobic quinolones, appears to be easily affected by an alteration in the efflux system. Thus, the decreased uptake of ciprofloxacin and norfloxacin may have been associated with the particularly high resistance of MS16405 to these drugs. Compared with ciprofloxacin and norfloxacin, ofloxacin and temafloxacin appear to be less affected by the alteration in the efflux system. This property may be explained by our finding that the hydrophobicities of these two drugs lie between those of ciprofloxacin or norfloxacin and sparfloxacin. In a previous report (34), Yoshida et al. described another type of quinolone-resistant isolate which exhibited high-level resistance to not only norfloxacin but sparfloxacin and a significant reduction in sparfloxacin uptake. This finding implies the presence of another efflux system which can excrete hydrophobic quinolones in S. aureus, or a further alteration in the efflux system for hydrophillic quinolones.
Recently, Yoshida et al. (33) reported that a norA gene which was cloned from a quinolone-resistant S. aureus strain (30) conferred relatively high resistance to hydrophilic quinolones, such as norfloxacin, enoxacin, ofloxacin, and ciprofloxacin, but only low or no resistance to hydrophobic quinolones, such as nalidixic acid and sparfloxacin, in S. aureus. They also showed that enoxacin uptake by S. aureus carrying the plasmid having the norA gene decreased by 50%, whereas the sparfloxacin uptake level was similar to that of the parent strain, SA113. Since the reduction of enoxacin uptake by the former strain was abolished by addition of CCCP, they speculated that the NorA polypeptide is a constituent of a membrane-associated active efflux pump of hydrophilic quinolones. Thus, it was implied that overproduction of the NorA protein is one of the fluoroquinolone resistance mechanisms in S. aureus. These findings also suggest that the active efflux system plays an important role in fluoroquinolone resistance in S. aureus.
Cohen et al. (4) reported the presence of an energydependent norfloxacin efflux pump in the inner membrane of quinolone-susceptible E. coli strains and suggested potential fluoroquinolone resistance mechanisms based on an increased gene dosage or expression of the carrier or an increased affinity of the efflux system for the fluoroquinolones. However, a mutation leading to such an alteration in a quinolone transport system in the cytoplasmic membrane has not been found. The presence of the drug efflux system implies, the possibility of resistance mechanisms for nonquinolone antibacterial agents, such as those reported with class A and B tetracycline resistance in E. coli (18) and class L (TetL) tetracycline resistance in streptococci (17) , which were found to be caused by energy-dependent decreased accumulation of the drug. However, we did not examine whether such resistance determinants are involved in the resistance to nonquinolone agents in MS16405. Further studies are important for elucidation of the mechanisms underlying the active efflux system for fluoroquinolones, its role in resistance, and its genetics in S. aureus.
